Related Experiment Video
Updated: Jan 7, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
524
Anatomical patterns at first confirmed relapse or refractory disease predict outcomes in diffuse large B-cell
Hidenori Hayashi1, Yohei Sasaki2, Ayano Shirai1
1Division of Hematology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8666, Japan.
International Journal of Hematology
|December 26, 2025
Summary
Multi-site involvement in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is a poor prognostic indicator. This finding impacts treatment strategies for patients with advanced disease.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presents diverse clinical outcomes.
- Prognostic significance of multi-site involvement at first relapse/refractory state is not well-defined.
Purpose of the Study:
- To investigate the prognostic impact of multi-site disease involvement at first relapse or refractory state in DLBCL.
- To identify key prognostic factors for progression-free survival (PFS) and overall survival (OS) in R/R DLBCL.
Main Methods:
- Retrospective analysis of 81 DLBCL patients experiencing first R/R.
- Assessment of clinical variables including number of involved sites, lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group performance status (ECOG PS).
Main Results:
- Multi-site involvement (≥2 sites) at first R/R significantly correlated with shorter PFS and OS.
- Multivariable analysis confirmed multi-site involvement as a strong independent prognostic factor for PFS and OS.
Conclusions:
- Multi-site disease at first R/R is an adverse prognostic feature in DLBCL.
- Disease distribution is crucial for prognosis and treatment planning in R/R DLBCL cases.
